BioClonetics Immunotherapeutics Overview
- Year Founded
-
2009
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
BioClonetics Immunotherapeutics General Information
Description
Developer of monoclonal antibodies intended to treat infectious diseases with non-toxic passive immunotherapy. The company specializes in developing biotechnology drugs from monoclonal antibodies such as Clone 3 antibody immunotherapy, enabling medical practitioners to treat cell lines that produce fully human monoclonal antibodies that target and neutralize infectious diseases including HIV, influenza, tetanus, and diphtheria.
Contact Information
Website
www.bioclonetics.com(Operating Subsidiary)
Corporate Office
- 1756 Bison Meadow Lane
- Heath, TX 75032
- United States
Corporate Office
- 1756 Bison Meadow Lane
- Heath, TX 75032
- United States
BioClonetics Immunotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 01-Dec-2020 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC | Completed | Pre-Clinical Trials | ||||
| 2. Angel (individual) | 02-Nov-2018 | $265K | $652K | Completed | Pre-Clinical Trials | |
| 1. Equity Crowdfunding | 30-Sep-2017 | $387K | $387K | Completed | Pre-Clinical Trials |
BioClonetics Immunotherapeutics Comparisons
Industry
Financing
Details
BioClonetics Immunotherapeutics Competitors (5)
One of BioClonetics Immunotherapeutics’s 5 competitors is Gilead Sciences, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Eli Lilly | Corporation | Indianapolis, IN | ||||
| GenScript | Formerly VC-backed | Piscataway, NJ | ||||
| Merck | Corporation | Darmstadt, Germany | ||||
| Johnson & Johnson | Corporation | New Brunswick, NJ |
BioClonetics Immunotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BioClonetics Immunotherapeutics Patents
BioClonetics Immunotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-0492560-A2 | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of hiv-1, and related peptides | Active | 26-Dec-1990 | ||
| EP-0492560-A3 | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of hiv-1, and related peptides | Active | 26-Dec-1990 | ||
| EP-0492560-B1 | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of hiv-1, and related peptides | Inactive | 26-Dec-1990 | ||
| EP-1016671-A2 | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (hiv-1) | Inactive | 26-Dec-1990 | ||
| EP-1016671-A3 | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (hiv-1) | Inactive | 26-Dec-1990 | C07K14/005 |
BioClonetics Immunotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BioClonetics Immunotherapeutics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ESM Ventures | Venture Capital | Minority |
BioClonetics Immunotherapeutics FAQs
-
When was BioClonetics Immunotherapeutics founded?
BioClonetics Immunotherapeutics was founded in 2009.
-
Where is BioClonetics Immunotherapeutics headquartered?
BioClonetics Immunotherapeutics is headquartered in Heath, TX.
-
What is the size of BioClonetics Immunotherapeutics?
BioClonetics Immunotherapeutics has 3 total employees.
-
What industry is BioClonetics Immunotherapeutics in?
BioClonetics Immunotherapeutics’s primary industry is Drug Discovery.
-
Is BioClonetics Immunotherapeutics a private or public company?
BioClonetics Immunotherapeutics is a Private company.
-
What is BioClonetics Immunotherapeutics’s current revenue?
The current revenue for BioClonetics Immunotherapeutics is .
-
How much funding has BioClonetics Immunotherapeutics raised over time?
BioClonetics Immunotherapeutics has raised $652K.
-
Who are BioClonetics Immunotherapeutics’s investors?
ESM Ventures has invested in BioClonetics Immunotherapeutics.
-
Who are BioClonetics Immunotherapeutics’s competitors?
Gilead Sciences, Eli Lilly, GenScript, Merck, and Johnson & Johnson are competitors of BioClonetics Immunotherapeutics.
-
When was BioClonetics Immunotherapeutics acquired?
BioClonetics Immunotherapeutics was acquired on 01-Dec-2020.
-
Who acquired BioClonetics Immunotherapeutics?
BioClonetics Immunotherapeutics was acquired by Enzolytics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
